Adult With Solid Cancer
Conditions
Keywords
liquid biopsy, solid cancer
Brief summary
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Interventions
BIOLOGICALBlood sampling for biomarker analysis (microRNA, circulating DNA…)
From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (\>18y) * Owing a social security insurance * Any solid cancer diagnosed by histopathology or cytology * Patient with blood sampling required as per standard of care * Informed consent signed
Exclusion criteria
* Refusal to participate * No blood sampling required as per standard of care * Hemoglobin \< 7g/dl (\< 9g/dl if respiratory or cardiovascular disease history) * Heterologous blood transfusion in the last 48 hours * Weight under 20 kg
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Liquid biopsy analyses | Day 0 | Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction. |
| Standard technics of disease assessment | Week 16 | Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells. |
| Correlation between outcome 1 and outcome 2 | year 5 | Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer. |
Countries
France
Contacts
CONTACTSebastian Couraud, MD, PhD
Outcome results
None listed